News >

Pembrolizumab Plus BL-8040 Shows Promise in Pancreatic Cancer

Angelica Welch
Published: Friday, Dec 28, 2018

Manuel Hidalgo, MD, PhD

Manuel Hidalgo, MD, PhD
The CXCR4 antagonist BL-8040 in combination with the PD-1 inhibitor pembrolizumab (Keytruda) showed promising survival data in a phase IIa trial of patients with metastatic pancreatic adenocarcinoma (NCT02826486). This study may serve as the gateway to immunotherapy for this population, according to lead investigator Manuel Hidalgo, MD, PhD.

, Hidalgo, professor of Medicine, Harvard Medical School, chief, Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, discussed the potential with BL-8040 and pembrolizumab in pancreatic adenocarcinoma.

OncLive: Can you please give an overview of this trial?

Hidalgo: This was a phase IIa trial of BL-8040, which is a CXCR4 inhibitor. By inhibiting this receptor, the drug facilitates the infiltration of T cells in the tumor. The trial was conducted in patients with advanced pancreatic cancer who had progressed after at least 1 prior line of chemotherapy. Many patients had more than 1 line [of treatment]. BL-8040 was given in combination with pembrolizumab. The idea behind this study is to prime the tumor by inhibiting CXCR4 signaling with BL-8040, allowing lymphocytes into the tumor, and then pembrolizumab is given with the intention to activate them to kill the tumor. Those are the basics.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Navigating Treatment Sequencing in Pancreatic Cancer: Experts Paving the Road Toward Patient-Centric CareAug 30, 20201.5
Publication Bottom Border
Border Publication